

Resource Summary Report

Generated by [dkNET](#) on Sep 19, 2026

L-02

RRID:CVCL_6926

Type: Cell Line

Proper Citation

Ubigen Cat# YC-D004, RRID:CVCL_6926

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_6926

Proper Citation: Ubigen Cat# YC-D004, RRID:CVCL_6926

Description: Cell line L-02 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Human papillomavirus-related endocervical adenocarcinoma

Defining Citation: [PMID:23498809](#), [PMID:23505090](#), [PMID:26116706](#), [PMID:26143199](#), [PMID:27027780](#)

Comments: Population: African American., Problematic cell line: Contaminated. Shown to be a HeLa derivative (PubMed=26116706). Originally thought to originate from a normal fetal liver..

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: L-02

Synonyms: L02, LO2, HL-7702, HL7702, Liver-02, Human Liver-7702

Cross References: BTO:BTO_0005965, ChEMBL-Cells:ChEMBL4295475, ChEMBL-Targets:ChEMBL4296457, GEO:GSM936770, KCB:KCB 200511YJ, PubChem_Cell_line:CVCL_6926, TOKU-E:3606, Ubigen:YC-D004, Wikidata:Q54900854

ID: CVCL_6926

Vendor: Ubigen

Catalog Number: YC-D004

Hierarchy: cvcl_0030

Record Creation Time: 20250130T072032+0000

Record Last Update: 20260913T011611+0000

Ratings and Alerts

No rating or validation information has been found for L-02.

Warning: Problematic cell line: Contaminated. Shown to be a HeLa derivative (PubMed=26116706). Originally thought to originate from a normal fetal liver.

Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00575.

Population: African American., Problematic cell line: Contaminated. Shown to be a HeLa derivative (PubMed=26116706). Originally thought to originate from a normal fetal liver..

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 923 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Dong Y, et al. (2026) KSRP-dependent immunogenic cell death induced by pyridazinone derivative IMB5036 drives antitumor immunity in neuroblastoma. FEBS letters.

Xu X, et al. (2026) Ultra-Radiostable Covalent Conformationally Interlocked Networks Enabling a Universal Radiometal-Labeling Platform for Cancer Radioembolization. Advanced science (Weinheim, Baden-Wurtemberg, Germany), e76278.

Wang W, et al. (2026) The rs713586 risk variant dysregulates ADCY3 rather than DNAJC27, leading to obesity through ZFP42-TET1-mediated DNA methylation. EBioMedicine, 123, 106112.

Shao Z, et al. (2026) Src-mediated PHB2 phosphorylation disrupts mitochondrial cristae through cardiolipin dissociation in hepatocellular carcinoma. Redox biology, 91, 104073.

Li Z, et al. (2026) Bio-inspired fractal-structured gel-drugs enable enhancing deep tumor penetration for efficient chemotherapy of hepatocellular carcinoma. Journal of controlled release : official journal of the Controlled Release Society, 394, 114899.

Shi H, et al. (2026) CENPA as a Genome Stability-Associated Biomarker in Hepatocellular Carcinoma: Multiomics Analysis and Experimental Validation. Human mutation, 2026,

9292971.

Hou H, et al. (2026) Design, Synthesis, and Biological Evaluation of Novel Tetrandrine Derivatives Targeting AKT1 for Hepatocellular Carcinoma Therapy: Integration of Network Pharmacology, Molecular Dynamics Simulation, and Experimental Validation. *ACS omega*, 11(21), 30812.

Wang B, et al. (2026) An ultrasensitive chemiluminescent probe for cysteine detection in food and biological samples. *Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy*, 363(Pt 2), 128383.

Xia Y, et al. (2025) Functional Modular Stacking Nanoprobes Based on Bimetallic Doped Carbon Dots for Multimodal Bioimaging and Photothermal Combined Tumor Therapy. *Advanced healthcare materials*, e04706.

Li Y, et al. (2025) LMNB2-mediated high PD-L1 transcription triggers the immune escape of hepatocellular carcinoma. *Cell death discovery*, 11(1), 269.

Chang S, et al. (2025) Succinate supplementation alleviates liver cancer by inhibiting the FN1/SQLE axis-mediated cholesterol biosynthesis. *iScience*, 28(2), 111731.

Wang X, et al. (2025) Berberine dissociates mitochondrial complex I by SIRT3-dependent deacetylation of NDUFS1 to improve hepatocellular glucose and lipid metabolism. *Science China. Life sciences*, 68(9), 2676.

Weiskirchen R, et al. (2025) Misidentified cell lines: failures of peer review, varying journal responses to misidentification inquiries, and strategies for safeguarding biomedical research. *Research integrity and peer review*, 10(1), 12.

Jiang J, et al. (2025) Hepatic sphingomyelin phosphodiesterase 3 promotes steatohepatitis by disrupting membrane sphingolipid metabolism. *Cell metabolism*, 37(5), 1119.

Zhou Y, et al. (2024) Prognostic, oncogenic roles, and pharmacogenomic features of AMD1 in hepatocellular carcinoma. *Cancer cell international*, 24(1), 398.

Mu M, et al. (2024) Targeting Ferroptosis-Elicited Inflammation Suppresses Hepatocellular Carcinoma Metastasis and Enhances Sorafenib Efficacy. *Cancer research*, 84(6), 841.

Shin GC, et al. (2024) Paraoxonase-2 agonist vutiglabin promotes autophagy activation and mitochondrial function to alleviate non-alcoholic steatohepatitis. *British journal of pharmacology*, 181(19), 3717.

Chen Z, et al. (2024) SIGLEC15, negatively correlated with PD-L1 in HCC, could induce CD8+ T cell apoptosis to promote immune evasion. *Oncoimmunology*, 13(1), 2376264.

Bai Y, et al. (2024) Silibinin, a commonly used therapeutic agent for non-alcohol fatty liver disease, functions through upregulating intestinal expression of fibroblast growth factor 15/19. *British journal of pharmacology*, 181(19), 3663.

Shen Y, et al. (2024) Coptisine exerts anti-tumour effects in triple-negative breast cancer by targeting mitochondrial complex I. *British journal of pharmacology*, 181(21), 4262.